Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Jenburkt Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Price Summary
| Previous Close | ₹1,067.55 |
|---|---|
| Day's Range | ₹1,054.30 - ₹1,106.90 |
| Open | ₹1,090.95 |
| 52 Week Range | ₹944.00 - ₹1,364.90 |
| Volume | 865 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 9.23 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 1.94 |
| Price/Earning (TTM) | 13.56 |
| TTM EPS (₹) | 78.71 |
| P/E Ratio | 13.93 |
| Book Value(₹) | 2.39 |
| PAT Margin (%) | 21.14 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 27.85 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 410.47 | 1516.92 |
| Expenses | N/A | N/A |
| PBT | 118.35 | 439.32 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 85.37 | 320.61 |
About Jenburkt Pharmaceuticals Ltd.
| Founded | 1985 |
|---|---|
| Managing Director | Ashish U Bhuta |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,66,178.79 | 1,942.95 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,96,095.00 | 7,386.75 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,91,530.43 | 5,042.00 | 3,468.00 - 3,468.00 |
| Apollo Hospitals Enterprise Ltd. | 1,28,516.16 | 8,940.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,318.19 | 1,417.10 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,12,693.00 | 1,129.75 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,001.57 | 2,408.50 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,274.12 | 1,083.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,068.24 | 2,550.00 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 98,742.15 | 1,183.00 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Wanbury informs about updates
Further to its letter dated 20th July, 2026, Wanbury has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in Annexure - I.
The above information is a part of company’s filings submitted to BSE.
SMS Pharmaceuticals informs about newspaper publication
Syschem India submits board meeting intimation
SMS Pharmaceuticals informs about disclosure
Granules India informs about audio recording of conference call
Pursuant to regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Granules India has informed that the audio recording of the earnings conference call of the Company for the Q1 of FY27 has been uploaded on the website of the Company at the below-mentioned link: https://granulesindia.com/investors/investor-resources/earnings-call-recording/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Jenburkt Pharmaceuticals Ltd. is ₹1,067.55 as of 2026-07-22.
The market capitalisation of Jenburkt Pharmaceuticals Ltd. is ₹471.14 as of 2026-07-22.
The 1-year return of Jenburkt Pharmaceuticals Ltd. is -253.65% as of 2025-07-21.
The P/E ratio of Jenburkt Pharmaceuticals Ltd. is 13.93 as of 2026-07-22.
The 52-week high and low of Jenburkt Pharmaceuticals Ltd. are ₹1,364.90 and ₹944.00, respectively, as of 2026-07-22.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
